MAKROCYCLISCHE INHIBITOREN DES HEPATITIS-C-VIRUS

Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(-O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LINDSTROEM, MATS STEFAN, SAHLBERG, SVEN CRISTER, WALLBERG, HANS, BELFRAGE, ANNA KARIN GERTRUD, ROSENQUIST, ASA ANNICA KRISTINA, DE KOCK, HERMAN, SAMUELSSON, BENGT BERTIL, KAHNBERG, PIA, RABOISSON, PIERRE, SIMMEN, KENNETH, HU, LILI, LINDQUIST, KARIN CHARLOTTA, WAEHLING, HORST JUERGEN, NILSSON, KARL MAGNUS, CLASSON, BJOERN
Format: Patent
Sprache:ger
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator LINDSTROEM, MATS STEFAN
SAHLBERG, SVEN CRISTER
WALLBERG, HANS
BELFRAGE, ANNA KARIN GERTRUD
ROSENQUIST, ASA ANNICA KRISTINA
DE KOCK, HERMAN
SAMUELSSON, BENGT BERTIL
KAHNBERG, PIA
RABOISSON, PIERRE
SIMMEN, KENNETH
HU, LILI
LINDQUIST, KARIN CHARLOTTA
WAEHLING, HORST JUERGEN
NILSSON, KARL MAGNUS
CLASSON, BJOERN
description Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(-O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ATE455775TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ATE455775TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ATE455775TT13</originalsourceid><addsrcrecordid>eNrjZDDwdfQO8neOdPbxDHb2cFXw9PPwdPIM8Q9y9VNwcQ1W8HANcAzxDPEM1nXWDfMMCg3mYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxjiGuJqam5uamISGGxsSoAQBXZSck</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MAKROCYCLISCHE INHIBITOREN DES HEPATITIS-C-VIRUS</title><source>esp@cenet</source><creator>LINDSTROEM, MATS STEFAN ; SAHLBERG, SVEN CRISTER ; WALLBERG, HANS ; BELFRAGE, ANNA KARIN GERTRUD ; ROSENQUIST, ASA ANNICA KRISTINA ; DE KOCK, HERMAN ; SAMUELSSON, BENGT BERTIL ; KAHNBERG, PIA ; RABOISSON, PIERRE ; SIMMEN, KENNETH ; HU, LILI ; LINDQUIST, KARIN CHARLOTTA ; WAEHLING, HORST JUERGEN ; NILSSON, KARL MAGNUS ; CLASSON, BJOERN</creator><creatorcontrib>LINDSTROEM, MATS STEFAN ; SAHLBERG, SVEN CRISTER ; WALLBERG, HANS ; BELFRAGE, ANNA KARIN GERTRUD ; ROSENQUIST, ASA ANNICA KRISTINA ; DE KOCK, HERMAN ; SAMUELSSON, BENGT BERTIL ; KAHNBERG, PIA ; RABOISSON, PIERRE ; SIMMEN, KENNETH ; HU, LILI ; LINDQUIST, KARIN CHARLOTTA ; WAEHLING, HORST JUERGEN ; NILSSON, KARL MAGNUS ; CLASSON, BJOERN</creatorcontrib><description>Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(-O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; &lt;img id="CUSTOM-CHARACTER-00001" he="2.46mm" wi="5.25mm" file="US07659245-20100209-P00001.TIF" alt="custom character" img-content="character" img-format="tif"/&gt; denotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.</description><language>ger</language><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20100215&amp;DB=EPODOC&amp;CC=AT&amp;NR=E455775T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20100215&amp;DB=EPODOC&amp;CC=AT&amp;NR=E455775T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LINDSTROEM, MATS STEFAN</creatorcontrib><creatorcontrib>SAHLBERG, SVEN CRISTER</creatorcontrib><creatorcontrib>WALLBERG, HANS</creatorcontrib><creatorcontrib>BELFRAGE, ANNA KARIN GERTRUD</creatorcontrib><creatorcontrib>ROSENQUIST, ASA ANNICA KRISTINA</creatorcontrib><creatorcontrib>DE KOCK, HERMAN</creatorcontrib><creatorcontrib>SAMUELSSON, BENGT BERTIL</creatorcontrib><creatorcontrib>KAHNBERG, PIA</creatorcontrib><creatorcontrib>RABOISSON, PIERRE</creatorcontrib><creatorcontrib>SIMMEN, KENNETH</creatorcontrib><creatorcontrib>HU, LILI</creatorcontrib><creatorcontrib>LINDQUIST, KARIN CHARLOTTA</creatorcontrib><creatorcontrib>WAEHLING, HORST JUERGEN</creatorcontrib><creatorcontrib>NILSSON, KARL MAGNUS</creatorcontrib><creatorcontrib>CLASSON, BJOERN</creatorcontrib><title>MAKROCYCLISCHE INHIBITOREN DES HEPATITIS-C-VIRUS</title><description>Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(-O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; &lt;img id="CUSTOM-CHARACTER-00001" he="2.46mm" wi="5.25mm" file="US07659245-20100209-P00001.TIF" alt="custom character" img-content="character" img-format="tif"/&gt; denotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDDwdfQO8neOdPbxDHb2cFXw9PPwdPIM8Q9y9VNwcQ1W8HANcAzxDPEM1nXWDfMMCg3mYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxjiGuJqam5uamISGGxsSoAQBXZSck</recordid><startdate>20100215</startdate><enddate>20100215</enddate><creator>LINDSTROEM, MATS STEFAN</creator><creator>SAHLBERG, SVEN CRISTER</creator><creator>WALLBERG, HANS</creator><creator>BELFRAGE, ANNA KARIN GERTRUD</creator><creator>ROSENQUIST, ASA ANNICA KRISTINA</creator><creator>DE KOCK, HERMAN</creator><creator>SAMUELSSON, BENGT BERTIL</creator><creator>KAHNBERG, PIA</creator><creator>RABOISSON, PIERRE</creator><creator>SIMMEN, KENNETH</creator><creator>HU, LILI</creator><creator>LINDQUIST, KARIN CHARLOTTA</creator><creator>WAEHLING, HORST JUERGEN</creator><creator>NILSSON, KARL MAGNUS</creator><creator>CLASSON, BJOERN</creator><scope>EVB</scope></search><sort><creationdate>20100215</creationdate><title>MAKROCYCLISCHE INHIBITOREN DES HEPATITIS-C-VIRUS</title><author>LINDSTROEM, MATS STEFAN ; SAHLBERG, SVEN CRISTER ; WALLBERG, HANS ; BELFRAGE, ANNA KARIN GERTRUD ; ROSENQUIST, ASA ANNICA KRISTINA ; DE KOCK, HERMAN ; SAMUELSSON, BENGT BERTIL ; KAHNBERG, PIA ; RABOISSON, PIERRE ; SIMMEN, KENNETH ; HU, LILI ; LINDQUIST, KARIN CHARLOTTA ; WAEHLING, HORST JUERGEN ; NILSSON, KARL MAGNUS ; CLASSON, BJOERN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ATE455775TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2010</creationdate><toplevel>online_resources</toplevel><creatorcontrib>LINDSTROEM, MATS STEFAN</creatorcontrib><creatorcontrib>SAHLBERG, SVEN CRISTER</creatorcontrib><creatorcontrib>WALLBERG, HANS</creatorcontrib><creatorcontrib>BELFRAGE, ANNA KARIN GERTRUD</creatorcontrib><creatorcontrib>ROSENQUIST, ASA ANNICA KRISTINA</creatorcontrib><creatorcontrib>DE KOCK, HERMAN</creatorcontrib><creatorcontrib>SAMUELSSON, BENGT BERTIL</creatorcontrib><creatorcontrib>KAHNBERG, PIA</creatorcontrib><creatorcontrib>RABOISSON, PIERRE</creatorcontrib><creatorcontrib>SIMMEN, KENNETH</creatorcontrib><creatorcontrib>HU, LILI</creatorcontrib><creatorcontrib>LINDQUIST, KARIN CHARLOTTA</creatorcontrib><creatorcontrib>WAEHLING, HORST JUERGEN</creatorcontrib><creatorcontrib>NILSSON, KARL MAGNUS</creatorcontrib><creatorcontrib>CLASSON, BJOERN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LINDSTROEM, MATS STEFAN</au><au>SAHLBERG, SVEN CRISTER</au><au>WALLBERG, HANS</au><au>BELFRAGE, ANNA KARIN GERTRUD</au><au>ROSENQUIST, ASA ANNICA KRISTINA</au><au>DE KOCK, HERMAN</au><au>SAMUELSSON, BENGT BERTIL</au><au>KAHNBERG, PIA</au><au>RABOISSON, PIERRE</au><au>SIMMEN, KENNETH</au><au>HU, LILI</au><au>LINDQUIST, KARIN CHARLOTTA</au><au>WAEHLING, HORST JUERGEN</au><au>NILSSON, KARL MAGNUS</au><au>CLASSON, BJOERN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MAKROCYCLISCHE INHIBITOREN DES HEPATITIS-C-VIRUS</title><date>2010-02-15</date><risdate>2010</risdate><abstract>Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(-O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; &lt;img id="CUSTOM-CHARACTER-00001" he="2.46mm" wi="5.25mm" file="US07659245-20100209-P00001.TIF" alt="custom character" img-content="character" img-format="tif"/&gt; denotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language ger
recordid cdi_epo_espacenet_ATE455775TT1
source esp@cenet
title MAKROCYCLISCHE INHIBITOREN DES HEPATITIS-C-VIRUS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T16%3A01%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LINDSTROEM,%20MATS%20STEFAN&rft.date=2010-02-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EATE455775TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true